XyloCor Therapeutics Completes Oversubscribed $41.9 Million Series A Financing To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease – Company closes additional $22.6 million in new financing – – Proceeds will fund initiation of new clinical trial for lead gene therapy candidate XC001 as …
Trending at Lumira Ventures
Edesa Biotech Completes Enrollment for Interim Clinical Study Milestone
TORONTO, ON / ACCESSWIRE / March 9, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has completed enrollment of the first cohort of a Phase 2b clinical study evaluating …
Fonds de solidarité FTQ Invest US$17.7 Million in Lumira IV Life Sciences Fund
Montréal, February 4, 2021 – As part of its strategy to support Québec’s life sciences sector through well-performing specialized funds, the Fonds de solidarité FTQ (“Fonds”) is investing US$17.7 million (C$22.5 million) in Lumira IV. Over the years, Lumira has …
FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved LUPKYNISTM (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis …
Lumira Ventures Appoints Special Advisors and Venture Partner
Veteran Pharmaceutical Industry Executives Will Advise Portfolio Companies and Investment Team TORONTO, November 18, 2020 – Lumira Ventures, a leading North American healthcare venture capital firm, today announced the appointment of Theodore Witek, Jr., DrPH, MBA and Daniel Billen, PhD …
Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio
Forbius’s Lead TGF-beta Asset, AVID200, is an Isoform-Selective TGF-beta Inhibitor, Currently in Phase 1 for Oncology and Fibrosis NEW YORK & MONTREAL– Bristol Myers Squibb (NYSE: BMY) and Forbius, a privately held, clinical-stage protein engineering company that designs and develops …
Antios Therapeutics Announces Publication Describing Preclinical Profile of ATI-2173
ATLANTA, Sept. 1, 2020 /PRNewswire/ — Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases, announced today the publication of preclinical results of ATI-2173, Antios’ lead oral drug candidate for …
enGene Receives Funding Through Cystic Fibrosis Foundation’s Path to a Cure for the Discovery of Novel Gene Therapies to Treat Cystic Fibrosis
OSTON and MONTRÉAL, Oct. 29, 2020 /PRNewswire/ -enGene Inc., a biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, announced today an award from the Cystic Fibrosis Foundation for the discovery of genetic medicines to treat patients …
G1 Therapeutics Announces Acceptance and Priority Review of NDA for Trilaciclib for Patients with Small Cell Lung Cancer
– PDUFA action date of February 15, 2021 assigned by U.S. Food and Drug Administration– Priority Review for trilaciclib is based on positive data from three randomized clinical trials showing robust myelopreservation benefits– G1 launching expanded access program (EAP) for …
Satsuma Pharmaceuticals Announces Enrollment of First Patient in the ASCEND™ Phase 3 open-label, safety trial of STS101
ASCEND results expected to support STS101 NDA filing in Q4 2021 SOUTH SAN FRANCISCO, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced the initiation of patient enrollment in the ASCEND …
Lumira continues to support those most affected by the COVID-19 pandemic
With a surge in new cases surpassing daily highs across the US, it is clear that the battle against COVID-19 will continue for the foreseeable future. While much of the world tries to go back to “normal”, healthcare workers on …
HistoSonics Announces $40 Million Financing
Breakthrough medical platform offers vision of non-invasive procedures to eliminate diseased tissues and tumors MINNEAPOLIS, June 8, 2020 /PRNewswire/ — HistoSonics, developer of a non-invasive robotic platform and sonic beam therapy, announced today that it has closed $40 million in an …
UCB Acquires Engage Therapeutics: Staccato® Alprazolam – A potential Solution for Acute On-demand Seizure Management for People Living With Epilepsy
– Staccato® Alprazolam could be a potential solution for 20-30% of epilepsy patients – Initial upfront payment of US$ 125 million and further potential milestone payments of up to US$ 145 million, total potential consideration of up to US$ 270 …
Forbius Reported Safety and Initial Anti-Fibrotic Effects of First-in-Class, Selective TGF-beta Inhibitor, AVID200, in Phase 1b Systemic Sclerosis Trial at EULAR 2020
Initial results demonstrate anti-fibrotic effects of AVID200 as indicated by rapid and sustained declines in skin fibrosis. AVID200 was well-tolerated, and no dose-limiting toxicities, SAEs or adverse events greater than Grade 2 were observed. The MTD was not reached. AVID200 …
Double Bottom Line Challenge Update: Lumira Ventures gives to five additional initiatives in our communities to support those in need during the COVID-19 crisis.
Over the past several weeks, we have seen a number of provinces and states relax restrictions and open up further. Combined with the start of summer, this has caused many to ease on social distancing measures some more so than …